Progress in the Research and Development of Anti-COVID-19 Drugs
The outbreaks of COVID-19 due to SARS-CoV-2 has caused serious physical and psychological damage to global human health. COVID-19 spread rapidly around the world in a short time. Confronted with such a highly infectious respiratory disease, the research and development of anti-COVID-19 drugs became an urgent work due to the lack of specific drugs for the treatment of COVID-19. Nevertheless, several existing drugs are available to relieve the clinical symptoms of COVID-19. We reviewed information on selected anti-SARS-CoV-2 candidate therapeutic agents published until June 2, 2020. We also discussed the strategies of the development of anti-COVID-19 drugs in the future. Our review provides a novel insight into the future development of a safer, efficient, and toxic-less anti-COVID-19 drug..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Frontiers in Public Health - 8(2020) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lianzhou Huang [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Anti-COVID-19 drugs |
|---|
| doi: |
10.3389/fpubh.2020.00365 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ000868248 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ000868248 | ||
| 003 | DE-627 | ||
| 005 | 20230503145246.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fpubh.2020.00365 |2 doi | |
| 035 | |a (DE-627)DOAJ000868248 | ||
| 035 | |a (DE-599)DOAJ56ee184966ec44d3b23341b507c41c24 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RA1-1270 | |
| 100 | 0 | |a Lianzhou Huang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Progress in the Research and Development of Anti-COVID-19 Drugs |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The outbreaks of COVID-19 due to SARS-CoV-2 has caused serious physical and psychological damage to global human health. COVID-19 spread rapidly around the world in a short time. Confronted with such a highly infectious respiratory disease, the research and development of anti-COVID-19 drugs became an urgent work due to the lack of specific drugs for the treatment of COVID-19. Nevertheless, several existing drugs are available to relieve the clinical symptoms of COVID-19. We reviewed information on selected anti-SARS-CoV-2 candidate therapeutic agents published until June 2, 2020. We also discussed the strategies of the development of anti-COVID-19 drugs in the future. Our review provides a novel insight into the future development of a safer, efficient, and toxic-less anti-COVID-19 drug. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a anti-COVID-19 drugs | |
| 650 | 4 | |a remdesivir | |
| 650 | 4 | |a lopinavir/ritonavir | |
| 650 | 4 | |a chloroquine | |
| 653 | 0 | |a Public aspects of medicine | |
| 700 | 0 | |a Yuanqiu Chen |e verfasserin |4 aut | |
| 700 | 0 | |a Ji Xiao |e verfasserin |4 aut | |
| 700 | 0 | |a Weisheng Luo |e verfasserin |4 aut | |
| 700 | 0 | |a Feng Li |e verfasserin |4 aut | |
| 700 | 0 | |a Yuan Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Yiliang Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Yifei Wang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Public Health |d Frontiers Media S.A., 2013 |g 8(2020) |w (DE-627)DOAJ000111538 |x 22962565 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2020 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fpubh.2020.00365 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/56ee184966ec44d3b23341b507c41c24 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/article/10.3389/fpubh.2020.00365/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2296-2565 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2020 | ||